ANGIOGENESIS PLAYERS
A FINANCIAL TIMES BIOFRONTIERS REPORT
(1999)
TABLE OF CONTENTS
EXECUTIVE SUMMARY
CHAPTER 1 MARKET AND TECHNOLOGY OVERVIEW
1.1 INTRODUCTION
1.1.1 Angiogenesis - an overview
1.1.2 Disease targets for anti-angiogenic therapy
* Cancer
* Established cancer therapies versus angiogenesis
inhibition
* Angiogenesis inhibition versus vascular targeting
* Cancer vaccines
* Kaposi's sarcoma
* Diabetic retinopathy and macular degeneration
* Other ophthalmic disorders
* Chronic inflammatory diseases
* Spinal cord injuries
1.1.3 Disease targets for angiogenic therapy
* Cardiovascular disease
* Wound repair
1.1.4 Types of drugs under development
1.2 APPROACHES TO ANGIOGENESIS INHIBITION
1.2.1 Inhibition of matrix metalloproteinases
1.2.2 Inhibition of growth factors
1.2.3 Inhibition of growth factor receptors
1.2.4 Inhibition of integrins
1.2.5 Inhibition of proteins required for angiogenesis
1.2.6 Supplementation with anti-angiogenic proteins
1.2.7 Supplementation with anti-angiogenic compounds
1.2.8 Use of antimicrobials and other pharmaceuticals
1.2.9 Cancer-specific strategies
* Tumour Vascular Targeting Agents
* Cancer vaccines
1.2.10 Gene therapy and other drug delivery systems
1.3 APPROACHES TO ANGIOGENESIS STIMULATION
1.3.1 Angiogenic therapy for cardiovascular disease
1.3.2 Angiogenic therapy for wound healing
1.3.3 Cardiovascular gene therapy
1.3.4 Adjunctive angiogenic therapy for TMR
1.4. Drug development and diagnostic applications
TABLE 1 INHIBITORS OF MATRIX METALLOPROTEINASES
TABLE 2 INHIBITORS OF GROWTH FACTORS
TABLE 3 INHIBITORS OF GROWTH FACTOR RECEPTORS
TABLE 4 INHIBITORS OF INTEGRINS
TABLE 5 INHIBITORS OF PROTEINS REQUIRED FOR ANGIOGENESIS
TABLE 6 ANTI-ANGIOGENIC PROTEINS
TABLE 7 ANTI-ANGIOGENIC COMPOUNDS
TABLE 8 ANTIMICROBIALS AND OTHER PHARMACEUTICALS
TABLE 9 CANCER-SPECIFIC STRATEGIES
TABLE 10 GENE THERAPY AND OTHER DRUG DELIVERY SYSTEMS
TABLE 11 ANGIOGENIC THERAPY
TABLE 12 CARDIOVASCULAR GENE THERAPY
TABLE 13 ANGIOGENIC ENHANCERS OF TMR
TABLE 14 DRUG DEVELOPMENT AND DIAGNOSTIC APPLICATIONS
TABLE 15 COLLABORATING COMPANIES
CHAPTER 2 COMPANY PROFILES
LIST OF COMPANIES PROFILED
ABBOTT LABORATORIES
Subsidiary (50%-owned): TAP Holdings Inc
ABGENIX INC
AETERNA LABORATORIES
AGOURON PHARMACEUTICALS INC
ALLERGAN INC
ALPHA 1 BIOMEDICALS INC
AMERICAN HOME PRODUCTS CORPORATION
Subsidiary: Wyeth-Ayerst Laboratories, Inc.
ANGIOTECH PHARMACEUTICALS INC
ANTICANCER INC
ANTISOMA PLC
ARIAD PHARMACEUTICALS INC
AVI BIOPHARMA INC
Formerly Antivirals, Inc.
BAYER AG
BIOCHEM PHARMA INC
Subsidiary: CliniChem Development Inc.
BIOMIRA INC
BIOSTRATUM INC
BOSTON LIFE SCIENCES INC
BOSTON SCIENTIFIC CORP
Subsidiary: CARDIOGENE THERAPEUTICS
BRISTOL MYERS SQUIBB COMPANY
BRITISH BIOTECH PLC
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
CARBOMED INC
CELGENE CORPORATION
CELL THERAPEUTICS INC
CELLTECH GROUP PLC
CELSION CORP
Formerly Cheung Laboratories Inc.
CEPHALON INC
CHIRON CORPORATION
Subsidiary: Chiron Therapeutics
CHIROSCIENCE GROUP PLC
CISTRON BIOTECHNOLOGY INC
COLLAGENEX PHARMACEUTICALS INC
COLLATERAL THERAPEUTICS INC
COLLGARD BIOPHARMACEUTICALS INC
CORVAS INTERNATIONAL INC
plans to acquire Vascular Genomics Inc.
CYTIMMUNE SCIENCES INC
CYTOGEN CORPORATION
Subsidiary: Targon Corp
CYTOTHERAPEUTICS INC
DELTAGEN INC
DEMEGEN BIOTECHNOLOGIES LTD
Formerly Demeter BioTechnologies, Ltd.
DUPONT, E.I., DE NEMOURS AND COMPANY
Subsidiary: DuPont PHarmaceuticals
ECLIPSE SURGICAL TECHNOLOGIES INC
Subsidiary: CardioGenesis Corporation
Subsidiary: Microheart Holding Inc
ELI LILLY & COMPANY
ENTREMED INC
EPIX MEDICAL INC
FIBROGEN INC
FIDIA SPA PHARMACEUTICAL COMPANY
GALDERMA LABORATORIES
GENEMEDICINE INC
merged with MEGABIOS
GENENTECH INC
GENERAL NUTRITION COMPANIES INC
GENETIX PHARMACEUTICALS INC
GENOMETRIX INC
GENVEC INC
GENZYME CORPORATION
HADASIT MEDICAL R&D SERVICES CO. LTD.
HOECHST MARION ROUSSEL INC
HUMAN GENOME SCIENCES INC
Subsidiary: Vascular Genetics Inc.
HYBRIDON INC
ILEX ONCOLOGY INC
IMCLONE SYSTEMS INC
INKINE PHARMACEUTICAL CO INC
Formerly Panax Pharmaceutical Co Ltd
INSITE VISION INC
INTEGRA LIFESCIENCES CORP
Subsidiary: Telios Pharmaceuticals
IXSYS INC
LIGAND PHARMACEUTICALS INC
Subsidiary: Glycomed Inc
LORUS THERAPEUTICS
Formerly Imutec Pharma
MAGAININ PHARMACEUTICALS INC
MEDCO RESEARCH INC
MEGABIOS CORP
Merged with GeneMedicine
MERCK KGaA
NEUROTECH
NEXSTAR PHARMACEUTICALS INC
NOVARTIS PHARMA AG
OSI PHARMACEUTICALS INC
Formerly Oncogene Science Inc.
OSIRIS THERAPEUTICS INC
OXIGENE INC
PARACELSIAN INC
PFIZER INC
PHARM-ECO LABORATORIES INC
PROCTER & GAMBLE INC
Subsidiary: Procter & Gamble Pharmaceuticals
PROGEN INDUSTRIES LTD
PROGENITOR INC
REGENERON PHARMACEUTICALS INC
REPLIGEN CORPORATION
RIBOZYME PHARMACEUTICALS INC
ROCHE HOLDING LTD
SCHERING AG
SCICLONE PHARMACEUTICALS INC
SCIOS INC
SELECTIVE GENETICS INC
Formerly Prizm Pharmaceuticals
SEQUUS PHARMACEUTICALS INC
SERVIER, LE GROUPE DE RECHERCHE
SHEFFIELD PHARMACEUTICALS INC
Formerly Sheffield Medical Technologies Inc
Subsidiary: Ion Pharmaceuticals
SMITHKLINE BEECHAM PLC
SUGEN INC
TAKEDA CHEMICAL INDUSTRIES LTD
Subsidiary (50%-owned): TAP Holdings Inc
TAP HOLDINGS INC
Subsidiary: TAP Pharmaceuticals Inc
TECHNICLONE INTERNATIONAL CORPORATION
Subsidiary: Peregrine Pharmaceuticals Inc.
TEXAS BIOTECHNOLOGY CORPORATION
TRIMEDYNE INC
Subsidiary: Cardiodyne Inc.
TSUMURA & CO
VASCULAR GENETICS INC
WARNER-LAMBERT COMPANY
Subsidiary: Parke Davis & Co Ltd
XOMA CORPORATION
ZENECA GROUP PLC
Subsidiary: Zeneca Pharmaceuticals Inc.
CHAPTER 3 FINANCIAL AND MARKET ANALYSES
3.1 Markets for angiogenic treatments
3.2 Angiogenesis company league tables
3.2.1 Top 70 Companies Ranked by Total Revenues
3.2.2 Top 70 Companies Ranked by Net Income/Loss
3.2.3 Top 70 Companies Ranked by Total Assets
3.2.4 Top 70 Companies Ranked by R&D Expenditure
CHAPTER 4 TRENDS AND OPPORTUNITIES
4.1 The markets for angiogenesis treatments are vast
4.2 Improved testing of angiogenesis drugs now possible
4.3 The search goes on for novel genes and drug targets
4.4 New hypothesis, new directions
4.5 Are anti-angiogenesis drugs already on the market?
4.6 Angiogenesis inhibition may complement vascular
destruction
4.7 Early cancer diagnosis may be possible
4.8 Unique endothelial markers are needed
4.9 New systems needed for delivery to heart
4.10 Gene therapy delivers in mice, promises much in humans
4.11 Angiogenesis-related patents change focus to inhibition
|
